Trial Profile

Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Sirolimus (Primary) ; Aspirin; Clopidogrel
Indications Coronary artery disease; Coronary artery restenosis; Embolism and thrombosis; Myocardial ischaemia
Focus Therapeutic Use
Acronyms EXCELLENT

Most Recent Events

30 Sep 2017 Results published in the Circulation Journal
16 Dec 2011 Results published in Circulation.
25 Oct 2011 Results published in the Journal of the American College of Cardiology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com